AGT and type 1 diabetes mellitus: Taken together, our results fully confirm, and extend to the model of experimental type 1 diabetes the beneficial effect of chronic AngIV treatment first reported by Vinh et al. in Apo-E deficient mice [19], and further establish that AngIV acts by increasing NO bioavailability and decreasing oxidative stress.